There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moleculin Biotech (MBRX – Research Report), Vir Biotechnology (VIR – Research Report) and SAB Biotherapeutics (SABS – Research Report) with bullish sentiments.
Moleculin Biotech (MBRX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech yesterday and set a price target of $3.00. The company’s shares closed last Tuesday at $0.56, close to its 52-week low of $0.34.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech with a $3.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Vir Biotechnology (VIR)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $95.00. The company’s shares closed last Tuesday at $9.75, close to its 52-week low of $7.72.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vir Biotechnology with a $32.86 average price target, a 244.4% upside from current levels. In a report issued on November 2, Leerink Partners also maintained a Buy rating on the stock with a $24.00 price target.
SAB Biotherapeutics (SABS)
H.C. Wainwright analyst Edward White reiterated a Buy rating on SAB Biotherapeutics today and set a price target of $1.00. The company’s shares closed last Tuesday at $0.94.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAB Biotherapeutics with a $2.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MBRX:
- Moleculin Biotech announces interim data in annamycin trials
- Moleculin Reports Third Quarter 2023 Financial Results
- Moleculin Biotech reports Q3 EPS (19c), consensus (24c)
- MBRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Moleculin Biotech’s Annamycin shows effiay in Phase 1B/2 lung sarcoma trial
